FDA supplemental approval: Morphine Sulfate (REMS)

AI Summary

This is an FDA supplemental approval granting REMS authorization for morphine sulfate extended-release capsules (30 mg, 60 mg, 90 mg, and 120 mg) by Actavis Elizabeth, effective 18 June 2026. The record documents a regulatory action to manage identified risks but contains no clinical trial results, efficacy data, or comparative evidence.

Plain-language summary

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for morphine sulfate extended-release capsules; indicates regulatory action to manage known risks but does not report clinical trial outcomes or efficacy data.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This record reflects FDA action on risk management requirements for an opioid product but does not provide clinical evidence to guide prescribing decisions. Clinicians should consult the approved product labeling and REMS requirements separately.

Caveats

• Record does not contain clinical trial results, efficacy data, or safety outcome numbers
• No comparative data or evidence of benefit over alternatives provided
• REMS approval indicates risk mitigation requirements but does not detail those requirements in this record
• Actual clinical utility and safety profile must be assessed from separate clinical or pharmacovigilance sources

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.